Cullinan Therapeutics Corporate Update and FY2025 Financial Results – Detailed Investor Analysis
Cullinan Therapeutics (Nasdaq: CGEM) Corporate Update and Full Year 2025 Financial Results
Key Highlights and Potentially Price-Sensitive Developments
-
Major Clinical Milestones Anticipated in 2026:
- Initial clinical data for CLN-978 in Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) expected in Q2 2026.
- Repeat dosing data for CLN-978 in RA confirmed for Q3 2026.
- Initial clinical data for CLN-978 in Sjögren’s disease expected in Q4 2026.
- Velinotamig Phase 1 data for SLE in China (via Genrix Bio) expected in Q4 2026.
-
Zipalertinib NDA Submission and Frontline Study Progress:
- Rolling NDA submission for zipalertinib (EGFR ex20ins inhibitor) completed (accelerated approval sought for EGFR ex20ins NSCLC).
- Pivotal REZILIENT3 frontline study fully enrolled; top-line results expected by year-end 2026.
- Cullinan eligible for substantial milestone payments (\$30M for 2L, up to \$100M for 1L U.S. regulatory approvals, plus a 50/50 U.S. profit share).
-
CLN-049 Fast Track and Registrational Progress:
- Compelling clinical data for CLN-049 (FLT3xCD3 bispecific T cell engager for AML) presented at ASH 2025; U.S. FDA Fast Track Designation.
- Company expects to advance CLN-049 rapidly to registrational development in AML, with dose escalation and expansion studies in 2026.
-
Strong Financial Position:
- Cash and investments at \$439.0 million as of December 31, 2025, with expected runway into 2029 under current operating plans.
- Total assets \$448.4 million; total liabilities \$39.6 million; shareholder equity \$408.7 million.
Detailed Financial Results – FY2025
-
R&D Expenses: \$42.9 million for Q4 2025 (up from \$40.5 million Q4 2024); \$187.4 million for FY2025 (up from \$142.9 million FY2024).
-
G&A Expenses: \$12.3 million for Q4 2025 (down from \$14.6 million Q4 2024); \$54.2 million for FY2025 (flat vs. \$54.0 million FY2024).
-
Net Loss: \$50.7 million for Q4 2025 (up from \$47.6 million Q4 2024); \$219.9 million for FY2025 (up from \$167.4 million FY2024).
-
Basic and Diluted Net Loss per Share (Common): \$(0.77) for Q4 2025; \$(3.36) for FY2025.
-
Weighted Average Shares Outstanding (Common): 59.2 million for Q4 2025.
Pipeline and Program Highlights
Immunology – CLN-978 & Velinotamig
-
CLN-978:
- Targets CD19xCD3 for T cell engagement in autoimmune diseases.
- Initial safety, B cell depletion, and biomarker/clinical activity data for SLE and RA expected Q2 2026.
- Repeat dosing data for RA expected Q3 2026; initial Sjögren’s disease data Q4 2026.
- Positioned as potential best-in-class therapy with subcutaneous administration for immune reset.
-
Velinotamig:
- BCMAxCD3 bispecific for autoimmune diseases.
- Phase 1 trial in China (SLE first, expansion planned); initial data Q4 2026. Cullinan to use data for global development.
Oncology – CLN-049 & Zipalertinib
-
CLN-049:
- Phase 1 dose escalation update for AML/MDS expected H2 2026.
- Monotherapy dose expansion (relapsed/refractory AML, TP53m AML) to start Q2 2026; enrollment completion and RP2D determination in Q4 2026.
- Phase 1/2 combination study in frontline AML to start Q4 2026.
- Parallel Phase 1 study in AML with measurable residual disease ongoing.
-
Zipalertinib:
- Rolling NDA submission completed (accelerated approval sought for locally advanced/metastatic EGFR ex20ins NSCLC post-platinum chemotherapy).
- REZILIENT3 pivotal 1L study fully enrolled; top-line results expected by year-end 2026.
- Potential for significant milestone payments and profit-sharing in U.S. upon regulatory approvals.
Implications for Shareholders
-
Multiple Catalysts in 2026: Several major data readouts and regulatory milestones may directly impact share price through pipeline validation, partnership revenue, and new market opportunities.
-
Strong Financial Position: Sufficient cash runway through at least 2029, supporting continued R&D and commercialization activities.
-
Potential for Significant Revenue: Milestone payments and profit share from zipalertinib, plus advancing high-impact therapies in autoimmune disease and oncology.
-
Risks: Increased net loss and R&D spending; milestones are dependent on successful clinical outcomes and regulatory approvals.
-
Fast Track and NDA Status: Regulatory progress (Fast Track, NDA) for CLN-049 and zipalertinib heightens near-term potential for value creation.
Contacts
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. The information is based on Cullinan Therapeutics’ official filings and press releases, which may contain forward-looking statements subject to significant risks and uncertainties. Actual results may differ materially from those anticipated. Investors should review all company filings and consult with their financial advisor before making investment decisions.
View Cullinan Therapeutics, Inc. Historical chart here
